Nexalin Technology (NXL) vs Valion Bio (VBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nexalin Technology is the larger company by market cap ($3.4 million vs $2.0 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | NXL | VBIO |
|---|---|---|
| Share price | $4.12 | $2.24 |
| Market cap | $3.42M | $1.99M |
| 1-day change | -4.63% | +2.28% |
| EPS (TTM) | $-14.10 | $-177.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.70 | $78.75 |
| 52-week low | $3.98 | $2.05 |
| Distance from 52-week high | -91.87% | -97.16% |
| Average volume | 1.01M | 1.46M |
| Shares outstanding | 829.40K | 887.59K |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
NXL vs VBIO FAQ
Which is bigger, Nexalin Technology or Valion Bio?
Nexalin Technology (NXL) is larger, with a market capitalization of $3.42M compared with $1.99M for Valion Bio (VBIO).
Are Nexalin Technology and Valion Bio in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.